mTOR – which stands for mammalian target of rapamycin – is a protein that regulates vital cell growth processes. mTOR receives external signals from growth factors, hormones, and proteins. It then gives the 'on' or 'off' signals for the cell to grow and divide, or nourish itself. If a cell's mTOR is not properly regulating...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Non-cancerous cells in the prostate contribute to the aquired tumor resistance to chemotherapy
Regretfully, metastatic forms of prostate cancer (spread to distant sites via the blood system) treated with chemotherapy often acquire resistance to the drug, partially due to the repetitive nature of treatment. Resistance leads to tumor progression and treatment failure. This scientific article proposes a novel therapeutic target named WNT16B that...
Read MoreCombined safety results of 4 clinical trials using sipuleucel-T in patients with prostate cancer
In a nutshell The present study summarized the outcomes of four clinical trials assessing the side-effects reported with sipuleucel-T treatment in patients with prostate cancer. The combined results indicated that this drug is relatively safe with mostly mild to moderate, short-term, and reversible side-effects. Some background As of...
Read MoreRisks versus benefit of the ‘HIPEC’ treatment for peritoneal metastases due to colorectal cancer
Colorectal cancer (CRC) often presents with peritoneal metastases, which have a poor outcome. This means that cancer cells have spread from the colon, appendix, or rectum to the peritoneum (a sheath that covers the abdominal organs). This article argues the pros and cons of a combined treatment for patients with peritoneal metastases from CRC. This...
Read More